Literature DB >> 62915

Cerebral atrophy and cognitive impairment in chronic schizophrenia.

C D Marsden.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 62915     DOI： 10.1016/s0140-6736(76)90984-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  8 in total

1.  Effects of trifluoperazine, chlorpromazine, and haloperidol upon temporal information processing by schizophrenic patients.

Authors:  S Goldstone; H G Nurnberg; W T Lhamon
Journal:  Psychopharmacology (Berl)       Date:  1979-10       Impact factor: 4.530

Review 2.  Very poor outcome schizophrenia: clinical and neuroimaging aspects.

Authors:  Serge A Mitelman; Monte S Buchsbaum
Journal:  Int Rev Psychiatry       Date:  2007-08

3.  Mistakes I Have Made in My Research Career.

Authors:  Robin M Murray
Journal:  Schizophr Bull       Date:  2017-03-01       Impact factor: 9.306

4.  Dementia as a complication of schizophrenia.

Authors:  P J de Vries; W G Honer; P M Kemp; P J McKenna
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-05       Impact factor: 10.154

5.  Stability of CT scan findings in schizophrenia: results of an 8 year follow-up study.

Authors:  B P Illowsky; D M Juliano; L B Bigelow; D R Weinberger
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-02       Impact factor: 10.154

6.  Memory in functional psychosis.

Authors:  J Cutting
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-11       Impact factor: 10.154

7.  Longitudinal regional brain volume loss in schizophrenia: Relationship to antipsychotic medication and change in social function.

Authors:  Joyce Y Guo; Sanna Huhtaniska; Jouko Miettunen; Erika Jääskeläinen; Vesa Kiviniemi; Juha Nikkinen; Jani Moilanen; Marianne Haapea; Pirjo Mäki; Peter B Jones; Juha Veijola; Matti Isohanni; Graham K Murray
Journal:  Schizophr Res       Date:  2015-07-16       Impact factor: 4.939

8.  Longitudinal changes in total brain volume in schizophrenia: relation to symptom severity, cognition and antipsychotic medication.

Authors:  Juha Veijola; Joyce Y Guo; Jani S Moilanen; Erika Jääskeläinen; Jouko Miettunen; Merja Kyllönen; Marianne Haapea; Sanna Huhtaniska; Antti Alaräisänen; Pirjo Mäki; Vesa Kiviniemi; Juha Nikkinen; Tuomo Starck; Jukka J Remes; Päivikki Tanskanen; Osmo Tervonen; Alle-Meije Wink; Angie Kehagia; John Suckling; Hiroyuki Kobayashi; Jennifer H Barnett; Anna Barnes; Hannu J Koponen; Peter B Jones; Matti Isohanni; Graham K Murray
Journal:  PLoS One       Date:  2014-07-18       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.